Scarica l'app Stockscreener
32.71
2.44%
0.78
Dopo l'orario di chiusura:
32.80
0.09
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.93
Aprire:
$32
Volume 24 ore:
866.58K
Relative Volume:
1.27
Capitalizzazione di mercato:
$2.04B
Reddito:
$32.08M
Utile/perdita netta:
$-169.77M
Rapporto P/E:
-11.51
EPS:
-2.8418
Flusso di cassa netto:
$-147.70M
1 W Prestazione:
+13.34%
1M Prestazione:
-0.94%
6M Prestazione:
+0.96%
1 anno Prestazione:
+146.87%
Intervallo 1D:
$31.62
$32.84
Intervallo di 1 settimana:
$28.19
$33.09
Portata 52W:
$12.86
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.71 | 1.83B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - BioSpace
Stoke Therapeutics Inc (STOK) Cash Flow - TradingKey
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STOK|Stoke Therapeutics Inc|Price:29.320|Chg%:+0.020 - TradingKey
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. Revenue Breakdown – NASDAQ:STOK - TradingView
Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Higher, Testing Resistance at $30.41ADD Alert - dars.gov.et
Stoke Therapeutics Inc (STOK) - MSN
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc For: 17 July - Investing.com India
Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 - BioSpace
Stoke Therapeutics grants CSO McCauley options for 225,000 shares at $29.91 each - Bitget
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat
Stoke Therapeutics (STOK) Declines Slightly as Stock Consolidates Near ResistanceStock Analysis - dars.gov.et
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo
Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com India
Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK
Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com
Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com
Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - AD HOC NEWS
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):